Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease
Alfredo Berruti(University of Turin), Luigi Dogliotti(Aarhus University Hospital), Roberto Mario Scarpa(Università Campus Bio-Medico), Enrico Bollito(Prostate Cancer UK), Alessandra Mosca(Higher Institute on Territorial Systems for Innovation), Andrea Saini(University of Turin), Federica Vana(University of Turin), M. Torta(Prostate Cancer UK), F. Porpiglia(Hospital de Galdakao), Marcello Tucci(University of Turin), Cecilia Maria Cracco(University of Turin), Mauro Papotti(University of Turin), Lucianna Russo(Prostate Cancer UK), Alberto Angeli(University of Turin), Susanna Cappia(University of Turin)
Cited by 89
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: Indications, Complications, and Outcomes in 5803 Patients
|Journal of Endourology|2011|818
A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery
|Annals of Surgery|2005|688